Primary Biliary Cholangitis clinical trials at UCSF
1 research study open to eligible people
Primary biliary cholangitis is a long-term liver disease that damages small bile ducts and can lead to scarring. UCSF is studying an oral medicine in people with PBC and compensated cirrhosis to see effects on clinical outcomes. UCSF is collecting safety data and liver test results.
Showing trials for
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
open to eligible people ages 18 years and up
To Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients with Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis.
San Francisco, California and other locations
Last updated: